NDAOPHTHALMICOINTMENT
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LUMI-SPORYN (bacitracin zinc; neomycin sulfate; polymyxin b sulfate) by R-Pharm US. Approved for infection in minor:. First approved in 1971.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMI-SPORYN is a triple-antibiotic ophthalmic ointment combining bacitracin zinc, neomycin sulfate, and polymyxin B sulfate for topical treatment of minor eye infections. This fixed-dose combination provides broad-spectrum coverage against common bacterial pathogens affecting the eye. It is applied directly to the affected eye area as an ointment formulation.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team focused on defending market position against generics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Positions linked to LUMI-SPORYN (0 current openings) typically focus on defending market share, managing generic transition, and optimizing cost structure rather than driving growth. Working on a LOE-approaching product offers experience in strategic pricing, channel management, and defensive market positioning—valuable skills for managing portfolio transitions in mature therapeutic categories.
Worked on LUMI-SPORYN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.